KARIN RAABERG: Open Payments
NPI 1346839297 · MONT VERNON, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,565 in 229 payments from 12 companies in 2025. Trend: 2023 $3,759 · 2024 $3,706 · 2025 $4,565
Food & beverage: $4,429Education: $135
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 67 | $1,456 |
| Otsuka America Pharmaceutical, Inc. | 35 | $434 |
| Alkermes, Inc. | 18 | $387 |
| E.R. Squibb & Sons, L.L.C. | 7 | $375 |
| ABBVIE INC. | 25 | $357 |
| Vanda Pharmaceuticals Inc. | 23 | $346 |
| Supernus Pharmaceuticals, Inc. | 14 | $317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $303 |
| Axsome Therapeutics, Inc. | 9 | $268 |
| Janssen Pharmaceuticals, Inc | 6 | $182 |
Products named: AUSTEDO XR, REXULTI, COBENFY, VRAYLAR, FANAPT, UZEDY, Qelbree, ARISTADA.
Industry payments across NH — which companies pay providers there.
